Crispr Therapeutics AG (CRSP) stock saw a decline, ending the day at $38.85 which represents a decrease of $-0.84 or -2.12% from the prior close of $39.69. The stock opened at $39.06 and touched a low ...

Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends ...

If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...

Dennison also describes how CRISPR screening tools will be key to further unraveling the mechanisms behind IBD. Current treatments for IBD are limited. They don't cure the disease and patients require ...

In a recent study, researchers from Uppsala University have shown that the Semliki Forest virus enters the central nervous ...

Synthego granted global license to manufacture and distribute AZ's CRISPR gene editing enzyme, eSpOT-ON.

The new Express License service removes barriers to accessing this transformative gene editing technology for startups.An ...

Achieved in vivo preclinical proof of concept of editing hematopoietic stem cells in non-human primates as a key step toward developing ...

Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.

Scribe announced its initial research collaboration with Sanofi for CRISPR-based cell therapies to address oncology ...

Ongoing launch of CASGEVY® continues to gain momentum--2025 is poised to be a catalyst-rich year with key updates across several ...